Home/Pipeline/CGB-600

CGB-600

Vitiligo

Phase 2Active

Key Facts

Indication

Vitiligo

Phase

Phase 2

Status

Active

Company

CAGE Bio

About CAGE Bio

CAGE Bio is a private, clinical-stage biotech founded in 2017 and based in Cambridge, Massachusetts. The company's core innovation is a deep eutectic ionic liquid (IL) platform designed to dramatically enhance skin permeation for a wide range of drug modalities, from small molecules to proteins and nucleic acids. This technology underpins a pipeline of localized therapies intended to treat serious skin conditions with high efficacy and improved safety profiles. The company is led by a seasoned team with extensive drug development and commercialization experience and has initiated its first clinical trial for vitiligo.

View full company profile

Therapeutic Areas

Dermatology Immunology Inflammation

Other Vitiligo Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
Adimune	Aditxt	Preclinical	Active
Vitiligo Candidate	Teva	Phase 2	Active
Therapeutic Vaccine	2A Pharma	Pre-clinical	Active
Vitiligo Trial	Well Pharma Medical Research	Not Specified	Active
AB1001	Ahammune Biosciences	Phase 1 Completed	Investigational New Drug
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 2	Active
Opzelura (ruxolitinib cream)	Incyte	Marketed	Active
Topical Roflumilast Foam 0.3%	Arcutis Biotherapeutics	Phase 2	Proof-of-concept ongoing
SCENESSE® (afamelanotide)	Clinuvel Pharmaceuticals	Phase III	Active (CUV156)
EB06	Edesa Biotech	Phase 1	Active